drugset / Trial / NCT00774605

A Study Evaluating The Absorption Of Varenicline Into The Body From A Varenicline Solution And A Varenicline Patch Applied To The Skin

NCT00774605

Phase 1 Completed 12 enrolled Pfizer
Non-randomizedParallel-groupOpen-label

Summary

To evaluate the absorption, safety, and tolerability of a varenicline solution and a varenicline patch applied to the skin.

Timeline

Start
2008-12
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Varenicline Small molecule 1.2 mg Topical
Subject Varenicline Small molecule 4.8 mg Topical

Indications

No indication recorded.